Plant ID: NPO9734
Plant Latin Name: Vincetoxicum hirundinaria
Taxonomy Genus: Vincetoxicum
Taxonomy Family: Apocynaceae
NCBI TaxonomyDB:
141524
Plant-of-the-World-Online:
102810-1
Diaphoretic; Diuretic; Emetic; Skin
Canada; Turkey; Italy; Nepal; France; Norway; Belarus; Algeria; Germany; Belgium; Kazakhstan; Spain; Ukraine; Netherlands; Denmark; Poland; Finland; United States; Morocco; Sweden; Switzerland; Russia; Bulgaria; Pakistan; Romania; Albania; Portugal; India; Austria; Greece; Hungary
GPR35; CNR2; | |
PTPN2; | |
ALPL; RECQL; TDP1; P4HB; HPGD; AKR1B1; NOX4; APEX1; POLB; | |
TEK; INSR; MET; EGFR; NUAK1; SRC; KDR; IGF1R; CSNK2A1; | |
NR1H4; | |
F10; | |
NFKB1; | |
SLC22A6; | |
SMAD3; HSPA1A; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 2.396E-10 | 3.069E-07 | EGFR, IGF1R, INSR, KDR, MET, TEK |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.266E-09 | 1.021E-06 | EGFR, F10, INSR, MET, NOX4, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.313E-09 | 2.834E-06 | EGFR, IGF1R, INSR, KDR, SRC |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 8.352E-09 | 3.712E-06 | AKR1B1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, NFKB1, NR1H4, SMAD3, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.044E-08 | 4.456E-06 | CNR2, NFKB1, NR1H4, PTPN2, SMAD3, TEK |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.034E-07 | 6.329E-05 | EGFR, INSR, KDR |
MF | GO:0003824; catalytic activity | GO:0003824; catalytic activity | 6.172E-07 | 1.581E-04 | AKR1B1, ALPL, APEX1, CSNK2A1, EGFR, F10, HPGD, HSPA1A, IGF1R, INSR, KDR, MET, NOX4, NUAK1, P4HB, POLB, PTPN2, RECQL, SRC, TDP1, TEK |
MF | Unclassified; | GO:0032403; protein complex binding | 7.782E-07 | 1.899E-04 | APEX1, EGFR, IGF1R, INSR, KDR, P4HB, PTPN2, SMAD3, SRC |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 9.274E-07 | 2.126E-04 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.882E-06 | 3.782E-04 | APEX1, POLB |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.100E-06 | 4.047E-04 | AKR1B1, APEX1, EGFR, KDR, NFKB1, SRC |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.084E-06 | 4.047E-04 | CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 7.054E-06 | 1.082E-03 | EGFR, KDR, NOX4, SRC, TEK |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.396E-06 | 1.118E-03 | ALPL, APEX1, EGFR, NFKB1, NOX4, SRC |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.292E-05 | 1.737E-03 | INSR, PTPN2, SRC |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.469E-05 | 1.950E-03 | AKR1B1, APEX1, EGFR, SRC |
BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 2.226E-05 | 2.708E-03 | AKR1B1, APEX1, KDR, NFKB1 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 2.334E-05 | 2.823E-03 | EGFR, HSPA1A, IGF1R, MET, NUAK1, P4HB, PTPN2 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 2.506E-05 | 2.966E-03 | EGFR, INSR, SMAD3 |
MF | Unclassified; | GO:0004872; receptor activity | 2.618E-05 | 3.049E-03 | CNR2, EGFR, GPR35, HPGD, IGF1R, INSR, KDR, MET, NR1H4, TEK |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.644E-05 | 3.063E-03 | NOX4, P4HB, SMAD3, SRC, TEK |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 3.934E-05 | 4.283E-03 | EGFR, POLB |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 6.087E-05 | 6.194E-03 | EGFR, IGF1R, INSR |
BP | GO:0009987; cellular process | GO:1902532; negative regulation of intracellular signal transduction | 6.549E-05 | 6.511E-03 | HSPA1A, IGF1R, MET, NR1H4, PTPN2, SRC |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 6.693E-05 | 6.595E-03 | INSR, NOX4, NR1H4, PTPN2 |
BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 7.197E-05 | 6.966E-03 | APEX1, INSR, NFKB1, SRC |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.420E-05 | 7.149E-03 | AKR1B1, APEX1, CSNK2A1, HPGD, HSPA1A, NFKB1, NR1H4, NUAK1, POLB, PTPN2, RECQL, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0032769; negative regulation of monooxygenase activity | 1.027E-04 | 9.053E-03 | CNR2, NFKB1 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.027E-04 | 9.053E-03 | IGF1R, INSR |
BP | GO:0040011; locomotion | GO:0014910; regulation of smooth muscle cell migration | 1.099E-04 | 9.574E-03 | APEX1, NOX4, SRC |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.940E-12 | 7.068E-10 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 9.776E-09 | 5.817E-07 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.619E-08 | 6.423E-07 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 4.009E-08 | 1.193E-06 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.608E-07 | 5.173E-06 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.423E-07 | 5.173E-06 | INSR, TEK, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.022E-06 | 3.437E-05 | SRC, MET, EGFR, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.903E-06 | 9.127E-05 | SRC, KDR, MET, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 6.739E-06 | 9.127E-05 | SRC, KDR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.913E-05 | 3.466E-04 | SMAD3, INSR, EGFR, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 8.653E-05 | 8.684E-04 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.692E-04 | 1.342E-03 | SMAD3, MET, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 9.487E-05 | 8.684E-04 | SMAD3, EGFR, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 9.472E-05 | 8.684E-04 | HPGD, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.180E-04 | 1.003E-03 | MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.306E-04 | 1.715E-03 | EGFR, NFKB1, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 2.710E-04 | 1.897E-03 | INSR, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.157E-04 | 2.087E-03 | SRC, EGFR, HSPA1A |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 7.982E-04 | 5.000E-03 | CSNK2A1, NFKB1, HSPA1A |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 9.803E-04 | 5.555E-03 | SMAD3, SRC, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.393E-03 | 7.536E-03 | SRC, EGFR |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 9.031E-04 | 5.373E-03 | POLB, APEX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; INSR; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
NA: NA | Christmas disease | NA | F10; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | AML | NA | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; AKR1B1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; |
C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; NFKB1; TEK; EGFR; SRC; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
NA: NA | Haemophilia B | NA | F10; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; IGF1R; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; SRC; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR; ALPL; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |